- Home
- JNVR vs ALLR Comparison
JNVR vs ALLR Comparison
Compare JNVR & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNVR
- ALLR
- Stock Information
- Founded
- JNVR 2018
- ALLR 2004
- Country
- JNVR United States
- ALLR United States
- Employees
- JNVR N/A
- ALLR N/A
- Industry
- JNVR Finance: Consumer Services
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- JNVR Finance
- ALLR Health Care
- Exchange
- JNVR Nasdaq
- ALLR Nasdaq
- Market Cap
- JNVR 93.3M
- ALLR 4.0M
- IPO Year
- JNVR 2023
- ALLR N/A
- Fundamental
- Price
- JNVR $63.99
- ALLR $1.07
- Analyst Decision
- JNVR
- ALLR
- Analyst Count
- JNVR 0
- ALLR 0
- Target Price
- JNVR N/A
- ALLR N/A
- AVG Volume (30 Days)
- JNVR 1.9M
- ALLR 1.2M
- Earning Date
- JNVR 05-13-2025
- ALLR 05-20-2025
- Dividend Yield
- JNVR N/A
- ALLR N/A
- EPS Growth
- JNVR N/A
- ALLR N/A
- EPS
- JNVR N/A
- ALLR N/A
- Revenue
- JNVR $2,099,660.00
- ALLR N/A
- Revenue This Year
- JNVR N/A
- ALLR N/A
- Revenue Next Year
- JNVR N/A
- ALLR N/A
- P/E Ratio
- JNVR N/A
- ALLR N/A
- Revenue Growth
- JNVR 4.82
- ALLR N/A
- 52 Week Low
- JNVR $3.37
- ALLR $0.61
- 52 Week High
- JNVR $91.38
- ALLR $25.47
- Technical
- Relative Strength Index (RSI)
- JNVR 57.60
- ALLR 54.54
- Support Level
- JNVR $64.09
- ALLR $1.01
- Resistance Level
- JNVR $91.38
- ALLR $1.23
- Average True Range (ATR)
- JNVR 14.99
- ALLR 0.11
- MACD
- JNVR -0.59
- ALLR 0.00
- Stochastic Oscillator
- JNVR 53.59
- ALLR 51.37
About JNVR Janover Inc.
Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from platform fees and subscription revenue.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.